BNZL:LSEBunzl plc Analysis
Data as of 2026-03-11 - not real-time
£2,234.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Bunzl plc trades around £2,234, roughly 12% above the DCF‑derived fair value of £1,938, indicating a near‑term pricing premium. The stock benefits from a solid 3.32% dividend yield supported by a comfortable 52.5% payout ratio and robust free cash flow, while technicals show a bullish bias – price sits above the 20‑day (2,167) and 50‑day (2,110) SMAs, MACD is bullish and RSI at 61 suggests upward momentum without being overbought. However, revenue growth is flat at 0.3% and margins remain modest, with a gross margin of only 7.7%. Recent news flags challenges in North America, noting that the group is “undoing the damage” and that rebuilding credibility will take time, adding a layer of operational uncertainty.
Given the low beta of 0.18 and a 30‑day volatility of 21.5%, market‑related risk is limited, but the combination of an overvalued price relative to fundamentals, modest growth prospects, and sector‑specific regulatory exposure suggests a cautious stance. The dividend remains sustainable, yet the high price‑to‑book multiple (≈258×) and the modest upside potential temper enthusiasm for new buying, especially for longer horizons.
Given the low beta of 0.18 and a 30‑day volatility of 21.5%, market‑related risk is limited, but the combination of an overvalued price relative to fundamentals, modest growth prospects, and sector‑specific regulatory exposure suggests a cautious stance. The dividend remains sustainable, yet the high price‑to‑book multiple (≈258×) and the modest upside potential temper enthusiasm for new buying, especially for longer horizons.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD and price above short‑term moving averages
- RSI at 61 indicating room for upside without overbought pressure
- Proximity to resistance around £2,270 limiting immediate upside
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Dividend yield of 3.32% with a sustainable payout ratio
- Flat revenue growth and modest margins reducing earnings upside
- Current price trading ~12% above DCF fair value
Long Term
> 3 yearsCautious
Model confidence: 6/10
Key Factors
- Overvaluation relative to DCF and high price‑to‑book multiple
- Limited revenue growth prospects in a mature consumer‑defensive sector
- Operational headwinds in North America affecting future credibility
Key Metrics & Analysis
Financial Health
Revenue Growth0.30%
Profit Margin3.88%
P/E Ratio15.8
ROE16.47%
ROA5.25%
Debt/Equity105.93
P/B Ratio258.2
Op. Cash Flow£913.0M
Free Cash Flow£615.8M
Technical Analysis
TrendNeutral
RSI61.7
Support£2,090.00
Resistance£2,270.00
MA 20£2,167.40
MA 50£2,109.82
MA 200£2,261.28
MACDBullish
VolumeIncreasing
Fear & Greed Index75.86
Valuation
Fair Value£1,938.11
Target Price£2,506.19
Upside/Downside12.18%
GradeOvervalued
TypeValue
Dividend Yield3.32%
Risk Assessment
Beta0.18
Volatility21.58%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.